Germantown-based Intrexon Corp. is swallowing up its fellow Montgomery County biotech, GenVec Inc., a small Gaithersburg gene therapy company that has been struggling to grow since its lead cancer drug candidate failed in late-stage trials in 2010. Intrexon (NYSE: XON) said GenVec’s (NASDAQ: GNVC) core value lies in its AdenoVerse gene delivery technology, which the larger company plans to combine with its own gene control systems to better target and treat cancer. Under the stock deal, GenVec…
from http://www.bizjournals.com/baltimore/news/2017/01/24/intrexon-to-acquire-fellow-md-biotech.html?ana=RSS%26s=article_search
via http://baltimorecheckbook.tumblr.com/post/156320217032
No comments:
Post a Comment